Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2021-08-02 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于公司产品获得美国FDA临床试验批准的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its product receiving FDA clinical trial approval. It includes details about the drug, its development status, market context, and risk warnings. The document is relatively short (1489 characters) and serves as a public disclosure of a regulatory milestone rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed regulatory filings like audit reports or annual reports. It is an announcement of a regulatory event related to product development. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-08-02 Chinese
天士力关于控股股东部分股份解质押及质押展期的公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement from the company TianShiLi Pharmaceutical Group Co., Ltd. regarding the partial release and extension of pledge of shares by the controlling shareholder. It details the number of shares pledged, released, and extended, along with percentages of total shares and shareholder holdings. The document includes tables with shareholding and pledge details, and discusses risk mitigation measures related to the pledge extension. There is no financial statement, earnings data, or management discussion of financial results. The document is a specific announcement about share pledging activities by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is 2708 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is MRQ with high confidence.
2021-08-02 Chinese
天士力关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from a company regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and references previous announcements related to the share buyback. The document is short (883 characters) and focuses on reporting the status of the share repurchase, which aligns with the definition of a Transaction in Own Shares (POS) filing. It is not an annual or quarterly report, nor a regulatory filing or announcement of a report publication. Therefore, the correct classification is POS.
2021-08-02 Chinese
天士力独立董事关于公司第八届董事会第3次会议相关事项的独立意见
Board/Management Information Classification · 90% confidence The document is an independent opinion from the independent directors regarding the extension of the duration of two employee stock ownership plans. It references compliance with relevant laws and regulations and confirms the board's procedures. The document is short (515 characters) and does not contain financial statements or detailed financial data. It is a formal opinion related to board matters but does not announce changes in board membership or senior management. It is not a full report, earnings release, or regulatory filing. Given the nature of the document as an independent director's opinion on board meeting matters, it fits best under Board/Management Information (MANG).
2021-07-23 Chinese
天士力关于员工持股计划展期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the extension of the duration of two employee stock ownership plans by the company TianShiLi Pharmaceutical Group Co., Ltd. It details board meetings, voting results, and compliance with regulatory guidelines. The content focuses on the status and extension of employee stock plans, which is a capital structure related update. The document is relatively short (2305 characters) and is an announcement rather than a detailed report or financial statement. It does not contain financial results, audit information, or management discussion. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as employee stock plans.
2021-07-23 Chinese
天士力关于T89预防及治疗急性高原反应申请美国新药上市临床试验进展情况暨风险提示公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of clinical trials and risk warnings related to a new drug application (T89) for prevention and treatment of acute mountain sickness. It includes information about the drug development status, market situation, and risk factors. The document is relatively short (1744 characters) and serves as a public disclosure or update rather than a detailed financial or regulatory report. It does not contain financial statements, audit information, or detailed management discussion. It is not a report of voting results, nor a call transcript or capital update. The content fits best with a Regulatory Filings (RNS) classification as it is a general regulatory announcement about clinical trial progress and risk disclosure without fitting into more specific categories.
2021-07-22 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.